Shares of companies that are studying vaccines for Ebola climbed after officials announced that the first case of the disease in the U.S.
While Hong Kong protesters brave tear gas to battle for democratic ideals, traders are making bets on how to profit.
A few areas could be affected by the Ebola news, the "Fast Money" traders say.
Sarepta has enough Ebola treatments for 100 patients, CEO Chris Garabedian says.
Get the best of CNBC in your inbox